LAWSUITS NEWS & LEGAL INFORMATION
Victoza Cancer Legal News Articles & Interviews
Victoza: EMA Moving Forward While FDA Idles Over Victoza and Cancer
May 30, 2014. By Gordon Gibb.
Washington, DC While cautious concern still exists with regard to Victoza side effects, the European Medicines Agency (EMA) has begun the process of actually allowing for expanded use of Victoza in the areas of the world governed by the EMA.
Read [ Victoza: EMA Moving Forward While FDA Idles Over Victoza and Cancer ]
Opinions Split on Victoza
May 1, 2014. By Heidi Turner.
Washington, DC Concerns about Victoza side effects, including a reported possible link between Victoza and cancer, have led to some critics requesting the type 2 diabetes drug be taken off the market. Not all studies, however, have confirmed the risk of cancer in patients taking Victoza.
Read [ Opinions Split on Victoza ]
FDA Plays Down Victoza Cancer Concern, but Plaintiffs Beg to Differ
March 19, 2014. By Gordon Gibb.
Washington, DC The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) may have agreed that there isn’t a lot to talk about with regard to Victoza side effects. To wit, the two health regulators have parked any provocative concern over pancreatitis and precancerous changes to the pancreas with regard to Victoza and other drugs in the incretin mimetics class. But that hasn’t stopped lawsuits brought by plaintiffs alleging Victoza and other similarly classed drugs did in their pancreas. And now the FDA is investigating another drug in the class over a concern for heart failure.
Read [ FDA Plays Down Victoza Cancer Concern, but Plaintiffs Beg to Differ ]
Studies Do Not Negate Victoza Cancer Concerns
February 21, 2014. By Gordon Gibb.
Washington, DC The word came down late last year that a peer-reviewed study on Victoza side effects determined that the injectable, once-per-day type 2 diabetes drug posed no greater risk of pancreatitis and pancreatic cancer than other oral antidiabetic agents. At the same time, however, study authors noted that the follow-up time of 15 months used for the purposes of the study may have been too short to properly document incidents of pancreatic cancer.
Read [ Studies Do Not Negate Victoza Cancer Concerns ]
FDA Still Unmoved by Victoza Side Effects
January 26, 2014. By Gordon Gibb.
Wilmington, NC In a letter appearing in at least two newspapers, the former executive director of the North Carolina Board of Pharmacy lamented the tendency for pharmaceutical ads to appear light-hearted and soothing, even though the context of the ad is far more serious. And while David Work of Wilmington was generalizing and not calling out any drug in particular, he used Victoza side effects to illustrate his point.
Read [ FDA Still Unmoved by Victoza Side Effects ]
New Study Suggests Link Between Victoza and Pancreatitis
December 26, 2013. By Heidi Turner.
Ferrara, Italy A new study by researchers in Italy suggests a link between Victoza and pancreatitis. The study, which appears to confirm previous findings about Victoza side effects, examined adverse drug reactions linked to drugs in the incretin mimetic group, a class of drugs that includes Victoza.
Read [ New Study Suggests Link Between Victoza and Pancreatitis ]
Will Push on Victoza See Increased Victoza Side Effects?
November 18, 2013. By Gordon Gibb.
Washington, DC The jury still appears to be out on Victoza side effects, with both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) taking a wait-and-see approach, eschewing any prospect of altering its position on the safety and efficacy of Victoza, but continuing to study liraglutide (Victoza) nevertheless.
Read [ Will Push on Victoza See Increased Victoza Side Effects? ]
Victoza Thyroid Cancer Reported to FDA, Now Reporting to Attorneys
October 16, 2013. By Jane Mundy.
Raleigh, NC Amanda’s Victoza side effects started a few years ago with gastrointestinal problems and nausea. Then she found a lump in her throat and was recently diagnosed with thyroid cancer, which she believes is Victoza cancer.
Read [ Victoza Thyroid Cancer Reported to FDA, Now Reporting to Attorneys ]
Januvia, Byetta, Janumet and Victoza Lawsuits Consolidated
September 19, 2013. By Heidi Turner.
Los Angeles, CA The Judicial Panel on multidistrict litigation has ordered that Januvia, Byetta, Janumet and Victoza lawsuits be consolidated for pre-trial proceedings. The motion to consolidate the lawsuits, which allege patients suffered Victoza side effects and side effects from similar drugs, was made by the plaintiffs, and although the judges noted that it is unusual to consolidate lawsuits involving competing drug companies, they felt allegations about pancreatic cancer were similar enough that the lawsuits could be consolidated.
Read [ Januvia, Byetta, Janumet and Victoza Lawsuits Consolidated ]
Will Continued Growth for Januvia Translate to Increased Januvia Side Effects?
February 19, 2013. By Gordon Gibb.
Whitehouse Station, NJ Anyone who may have hoped that a new diabetes drug manufactured by Johnson & Johnson (J&J) could prove a worthy alternative to Merck’s Januvia, and therefore stem Januvia side effects, could wind up somewhat disappointed following speculation that sales of Januvia could continue to grow, even in the face of competition from J&J.
Read [ Will Continued Growth for Januvia Translate to Increased Januvia Side Effects? ]
- New Diabetes Drug May Compete with Januvia By Heidi Turner (Feb-2-13)
- Januvia Patients Face Increased Risk of Pancreatitis By Heidi Turner (Nov-3-12)
- FDA Petitioned to Remove Diabetes Med Victoza (Liraglutide) from the Market By Lucy Campbell (May-30-12)
- Drug Company That Sells Januvia Acquires SmartCells By Charles Benson (Jan-3-11)